fb-pixel tracker

Profile Menu

MI Profile for New York Statechange location

MI Profile is a multi-platform, solid tumor biomarker analysis for therapeutic decision support and clinical trials matching. Technologies used to asses DNA, RNA and Protiens include, Next-Generation Sequencing DNA/RNA (also called MI Tumor Seek), Pyro Sequencing, Fragment Analysis, Immunohistochemistry and Chromogenic in situ Hybridization.

The information below details the biomarkers tested and technology platforms utilized by tumor type.


  • In certain instances, some biomarkers included in MI Profile or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibody 22c3 or antibody SP-142 are available upon request.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.
  • For certain patients, MSI testing is performed by Fragment Analysis.
  • For all cases with an MSI result of equivocal, MMR IHCs (MLH1, MSH2, MSH6, PMS2) will be performed.
  • The following TAPUR NGS genes are available upon request: EPHA2, FYN, GLI2, LYN, POLD1, MST1R, YES1, and NGS Fusion: Bcrl-abl.
Share This Page

Precision Oncology Starts Here

Uncover molecular insights through comprehensive interrogation of DNA, RNA and Proteins to personalize treatment options.


Loading Biomarkers...